Humira Biosimilar Market Report 2026

The humira biosimilar market size has grown rapidly in recent years. It will grow from $3.67 billion in 2025 to $4.12 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to patent expiry of humira, high treatment costs of branded biologics, increasing prevalence of autoimmune diseases, regulatory support for biosimilar approvals, payer pressure to reduce biologic drug spending.

The humira biosimilar market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to wider adoption of biosimilars in clinical practice, expansion of reimbursement support for biosimilars, increasing physician confidence in biosimilar efficacy, growth of interchangeable biosimilar approvals, rising patient access initiatives for affordable biologics. Major trends in the forecast period include expanding adoption of adalimumab biosimilars across autoimmune indications, increasing focus on cost containment in biologic therapies, growing acceptance of interchangeable biosimilars by healthcare providers, rising demand for high-concentration and citrate-free formulations, intensifying competition among biosimilar manufacturers.

The rising prevalence of autoimmune diseases is expected to drive the growth of the Humira biosimilar market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy cells, tissues, or organs. This increasing prevalence is linked to factors such as environmental pollution, which can disrupt immune function and increase the risk of autoimmune reactions. Humira biosimilars work by blocking tumor necrosis factor (TNF), a protein that promotes inflammation in autoimmune diseases, thereby reducing immune response, alleviating symptoms, and preventing damage to healthy tissues. For example, in August 2024, Public Health Scotland reported that the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients in 2023. Consequently, the growing prevalence of autoimmune disorders is propelling the Humira biosimilar market.

Key companies in the Humira biosimilar market are developing advanced products, such as TNF blockers, to provide more affordable treatment options for autoimmune disease management. TNF blockers are biologic medications that inhibit the action of TNF, a protein that drives inflammation. For instance, in July 2023, Organon & Co., a US-based pharmaceutical company, partnered with Samsung Bioepis Co., Ltd., a South Korea-based biotech company, to launch HADLIMA, a biosimilar to Humira. HADLIMA is available in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) formulations, mirroring the options of the originator Humira. It is offered at a significant discount - approximately 85% lower than Humira’s list price - and includes patient support programs. This launch followed a global settlement allowing U.S. supply and represents a key step in expanding treatment options for chronic autoimmune diseases in the U.S.

In February 2024, Alvotech, a Luxembourg-based biotech company, partnered with Teva Pharmaceuticals to enhance access to Humira biosimilars in the U.S. The collaboration introduced SIMLANDI, the first high-concentration, citrate-free interchangeable biosimilar to Humira in the U.S., aiming to increase patient access, foster biosimilar competition, reduce treatment costs, and improve outcomes. Teva Pharmaceuticals is a US-based pharmaceutical company focused on providing high-quality, affordable therapies.

Major companies operating in the humira biosimilar market are Amgen Inc., Pfizer Inc., Samsung Biologics, Biocon Limited, Celltrion Inc., Boehringer Ingelheim GmbH, Sandoz Group AG, Fresenius Kabi AG, Alvotech, Coherus BioSciences Inc., Zydus Lifesciences Ltd., Hetero Drugs Ltd., LG Chem Ltd., Torrent Pharmaceuticals Ltd., Fujifilm Holdings Corporation, Teva Pharmaceutical Industries Ltd., Merck KGaA, Organon & Co., Cipla Limited, Dr. Reddy’s Laboratories Ltd.

North America was the largest region in the humira biosimilar market in 2025. The regions covered in the humira biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the humira biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the humira biosimilar market by increasing the cost of imported active pharmaceutical ingredients, biologic manufacturing inputs, and specialized bioprocessing equipment. These effects are most pronounced in biosimilar production and formulation segments and in regions such as North America and Europe that rely on global biologics supply chains. While higher costs may pressure pricing strategies, tariffs are also encouraging local manufacturing, regional sourcing of biologic inputs, and investment in domestic biosimilar production capacity, supporting long-term market competitiveness.

The humira biosimilar market research report is one of a series of new reports that provides humira biosimilar market statistics, including humira biosimilar industry global market size, regional shares, competitors with a humira biosimilar market share, detailed humira biosimilar market segments, market trends and opportunities, and any further data you may need to thrive in the humira biosimilar industry. This humira biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A Humira biosimilar is a biologic medication designed to closely replicate Humira for the treatment of autoimmune disorders. It provides the same safety, efficacy, and quality as the original drug, while generally being more affordable. By offering a cost-effective alternative, Humira biosimilars improve patient access to treatment and contribute to reducing overall healthcare costs.

The primary product types of Humira biosimilars include adalimumab biosimilars and others. Adalimumab biosimilars are biologic drugs that closely resemble the reference anti-TNF therapy Humira, delivering equivalent safety, efficacy, and quality in managing autoimmune conditions. These products are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are used to treat conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and others.

The humira biosimilar market consists of sales of prefilled syringes, autoinjector (AI) pens, and vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.